[ad_1]
Despite the serious side effects that the government and international organizations have warned about hydroxychloroquine, used to treat malaria, many Covid-19 patients prefer to use it.
In Mexico, hospitals have exhausted their reserve of enough patients who are now ordering by name, although their suitability to treat a good disease has not been confirmed.
After the United States Food and Drug Administration (FDA) allowed the use of national stocks of hydroxychloroquine and another similar treatment called “chloroquine” to treat patients with Covid-19, this was interpreted by many as a sign of the agency’s confidence in the effectiveness of these drugs, leading to a race to obtain them or to their hoarding and, therefore, a global shortage.
The journal Nature said in a report that “enthusiasm” around these two drugs created a shortage of supplies and negatively affected the registration of other possible treatments in clinical trials.
Dr. Daniel Cowell, an infectious disease specialist at the University of Michigan School of Medicine, said: “When you have desperate people and doctors, you want to believe that you have a successful medication.”
“But in the end, this doesn’t help anyone if the drug isn’t effective, and it prevents people from participating in other studies.”
Many Covid-19 patients are unwilling to participate in clinical trials that require them to discontinue chloroquine therapies, making it difficult for individuals to enroll in ad hoc experiences to learn about the possibility of using other drugs, such as anti-drugs HIV, according to infectious disease specialist Song Han Kim of the Ulsan University School of Medicine in South Korea.
Psychiatrist Eric Linzi of the University of Washington in St. Louis, Missouri also suffers the same: he designed an antidepressant trial to see its ability to reduce the immune response associated with some cases of Covid-19, but only 10 participants enrolled. in the trial so far, and three declined. Others participate because they intend to use hydroxychloroquine.
As a result, some researchers make concessions in study design. In Iran, pathologist Ali Reza Ghaffarih abandoned his plans to exclude chloroquine treatment from his experience with a drug at Kermanshah University of Medical Sciences, after participants refused to abandon it, and hopes this does not complicate the interpretation. of your results for the experiment.
Prashant Malhotra, an infectious disease specialist at North Shore University Hospital in New York, warns that delays in registering for clinical trials can put trials at risk, especially during a pandemic. In some outbreaks, he believes that it is better for trials to be completed early, because with increased pressure on healthcare systems, the quality of care may decline.
Recent studies have not conclusively shown whether chloroquine or hydroxychloroquine can benefit Covid-19 patients, but some have warned that it can harm people with the disease.
Research has found that hydroxychloroquine, an antimalarial drug that is also used to treat lupus and rheumatoid arthritis, causes heart beat problems, which could lead to death.
The French Medicines Agency renewed on Saturday its warning to doctors against the use of hydroxychloroquine in the fight against Covid-19, and the head of the agency, Adumenique Martin, stated that “Covid patients generally suffer from a weak heart, so they are likely to have problems with medications that affect heart health. “
The US National Institutes of Health. USA They also confirmed that there is insufficient data to recommend whether or not to use chloroquine and hydroxychloroquine in people with good disease.
